Rimonabant CAS No 168273-06-1

Super Pure Weight Loss Steroids USP Grade Weight Loss Drug s Rimonabant Bodybuilding Steroids Raw White Powder CAS:168273-06-1 Quick Details: Description : Rimonabant / Acomplia selectively blocks the CB1 receptors that are present in the brain and other peripheral organs important in fat/lipid...
Product Details

Super Pure Weight Loss Steroids USP Grade Weight Loss Drugs Rimonabant Bodybuilding Steroids Raw White Powder CAS:168273-06-1

Quick Details:

Product Name

Rimonabant

CAS No

168273-06-1

MF

C22H21Cl3N4O

MW

463.79

Mol File

168273-06-1.mol

Assay

99%

Storage temp

2-8°C

Usage

Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane

Shipping

EMS , FedEx , TNT , DHL , UPS

Delivery

Express Courier

Brand

NJBN STEROID

Appearance

White Crystalline Powder

Export Markets

Global

Sample

Free

Package

Discreet and safe packages according to different countries

Product Categories:

Weight Loss;SR141716


 Description :  
 Rimonabant / Acomplia selectively blocks the CB1 receptors that are present in the brain and other peripheral organs important in fat/lipid and glucose metabolism, including muscle, gastrointestinal tract, liver and adipose tissue. Basically, it switches off those brain circuits that are responsible for making people hungry while smoking . Acomplia, along with CB1 receptors, reduces the EC system's over-activity.   
 Rimonabant / Acomplia is said to have reduced the overall body fat by 10% in one out of three users. Also, it is reported that those users did not gain back more than a kilo over the next two years if the patients remained on Rimonabant. Rimonabant was recommended for those with a BMI of 30 or greater, who were considered obese, and is most successful when combined with exercise and a proper diet.
 
 Function :
 Rimonabant / Acomplia is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. 
  
 Rimonabant / Acomplia,Developed by Sanofi-Aventis, Acomplia (Rimonabant) is a selective CB1 receptor antagonist. In other words, Rimonabant is intended to promote weight loss by reducing the total number of calories an individual consumes on a daily basis.
  
Rimonabant / Acomplia works by blocking endogenous from binding to neuronal CB1 receptors. The activation of these receptors by endogenous , such as anadamide, increases an individuals appetite. By blocking the activation of the receptors, appetite suppression may occur.

 

blob.png

blob.png

blob.png

blob.png

blob.png


Hot Tags: rimonabant CAS No 168273-06-1, China, suppliers, wholesale, buy
Feedback